HCVguidelines.org, the website developed by IDSA and the American Association for the Study of Liver Diseases (AASLD) to provide up-to-date guidance on the treatment of hepatitis C (HCV), has released updates on several sections of the website based on newly available therapies and data.
The latest release of the guidance reflects several important developments, including the recent approval of the second single-tablet fixed dose combination regimen (elbasvir/grazoprevir) for the treatment of HCV. Based on the approval of this regimen, the website now also includes guidance on the role of testing for resistance to some HCV medications that may exist in patients prior to starting therapy.
While most sections of the guidance have been updated, the most significant changes have been made in the Initial Treatment of HCV Infection and Retreatment of Persons in Whom Prior Treatment Has Failed sections as well as the Unique Populations sections, which include patients living with HIV, kidney disease, and severe liver disease including those with severe liver dysfunction and those who have had a liver transplant. Updated references have been provided throughout the guidance.
for updates regarding the release of this and other sections of the guidance.
< Previous Article | Next Article >